MRCP2-1266
A 63-year-old woman presents for her diabetic review. She has type-2 diabetes and suffered an NSTEMI 3 months ago, resulting in a decrease in her ejection fraction. Her current medication includes metformin 500mg TDS, aspirin, statin, bisoprolol, and ramipril.
The patient’s pre-clinic blood results are as follows:
– HbA1c 59 mmol/mol (<42 mmol/mol)
– Urea 8.3 mmol/L (2.0 – 7.0)
– Creatinine 140 µmol/L (55 – 120)
– eGFR 32.8mL/min/1.73m²
Her BMI is 28.7kg/m², with a weight of 62 kg and a height of 147 cm. She recently attended a retinal screening appointment and was informed of pre-proliferative diabetic retinopathy changes. A follow-up appointment with the renal team regarding her diabetic nephropathy is scheduled for 2 weeks from now.
The patient’s main concern is experiencing hypoglycemia episodes, as she lives alone and would prefer to avoid increasing her risk of hypos if possible. What would be the most appropriate course of action regarding her oral anti-diabetic agents?